CN102805791B - Drug composition for treating rheumatic pain - Google Patents
Drug composition for treating rheumatic pain Download PDFInfo
- Publication number
- CN102805791B CN102805791B CN201210286475.2A CN201210286475A CN102805791B CN 102805791 B CN102805791 B CN 102805791B CN 201210286475 A CN201210286475 A CN 201210286475A CN 102805791 B CN102805791 B CN 102805791B
- Authority
- CN
- China
- Prior art keywords
- drug composition
- pain
- pharmaceutical composition
- treatment
- treating rheumatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a drug composition for treating rheumatic pain. The drug composition consists of euphorbia kansui, venenum bufonis, paris rhizome, bezoar from monkeys, gecko, turpentine, caulis trachelospermi, notopterygium root, folium photiniae, centipede, sangusis draconis and geranium wilfordii. The drug composition is added with conventional auxiliary materials according to a conventional process to be prepared into plaster, spray, ointment, liniment or tincture which is accepted clinically. The drug composition has good treatment effects of warming and activating meridians, promoting blood circulation to remove blood stasis, relieving swelling and pain, dispelling wind, dehumidifying and treating rheumatic pain and has no toxic and side effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, particularly relate to a kind of pharmaceutical composition for the treatment of rheumatalgia.
Background technology
Rheumatalgia, its disease belongs to paralysis one class, and the traditional Chinese medical science is thought the disease due to wind and wet two kinds of pathogenic factor combination.Disease opinion has headache, heating, slight perspiration, aversion to wind, heavy sensation of the body, dysuria, joint to ache, can not bend and stretch etc.Arthropathy, is outbreak and alleviates the chronic course of disease alternately outward still with swelling and moving obstacle apart from pain.Because patient's blood circulation is obstructed, cause muscle or organize needed nutrition to carry by blood circulation, cause patient's muscle to lack nutrition and accelerated ageing becomes stiff, serious meeting causes patient's muscle and blood vessel atrophy, some patients were and can occur that joint disables and viscera function exhaustion.Bi condition is to wait exopathogen invasion because wind and cold is damp and hot, impatency meridians joint, QI-blood circulation is not smooth, main clinical manifestation be whole body joint be migration red, swell, weighing, pain.Often refer to rheumatic arthritis.
Summary of the invention
The object of the invention is to provide a kind of pharmaceutical composition for the treatment of rheumatalgia.
The present invention is achieved through the following technical solutions:
The crude drug of pharmaceutical composition of the present invention consists of:
Venenum Bufonis 5-15 weight portion Gekko Swinhonis 5-15 weight portion Caulis Trachelospermi 5-15 weight portion
Rhizoma Et Radix Notopterygii 5-15 weight portion Scolopendra 5-15 weight portion Sanguis Draxonis 5-15 weight portion
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Venenum Bufonis 10 weight portion Gekko Swinhonis 10 weight portion Caulis Trachelospermi 10 weight portions
Rhizoma Et Radix Notopterygii 10 weight portion Scolopendra 10 weight portion Sanguis Draxonis 10 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Venenum Bufonis 7 weight portion Gekko Swinhonis 13 weight portion Caulis Trachelospermi 7 weight portions
Rhizoma Et Radix Notopterygii 13 weight portion Scolopendra 7 weight portion Sanguis Draxonis 13 weight portions.
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Venenum Bufonis 13 weight portion Gekko Swinhonis 7 weight portion Caulis Trachelospermi 13 weight portions
Rhizoma Et Radix Notopterygii 7 weight portion Scolopendra 13 weight portion Sanguis Draxonis 7 weight portions.
The crude drug composition of pharmaceutical composition of the present invention can also be:
The crude drug composition of pharmaceutical composition of the present invention is preferably:
The crude drug composition of pharmaceutical composition of the present invention is preferably:
The crude drug composition of pharmaceutical composition of the present invention is preferably:
Pharmaceutical composition of the present invention adds conventional adjuvant to make the emplastrum of clinical acceptance, spray, ointment, liniment or tincture according to common process.
Pharmaceutical composition of the present invention has promoting the flow of QI in the collateral by warming the meridian, and blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, evil-wind expelling and dampness removing have good therapeutical effect to treatment rheumatalgia, and have no side effect.
Experimental example is used for further illustrating the present invention below, but is not limited to the present invention.
One, experimental example
1, clinical observation
Emplastrum of the present invention (according to embodiment 1 method preparation) treatment rheumatalgia 100 examples, wherein male's 50 examples, women's 50 examples.
Select matched group treating rheumatism and strengthening bone to paste, by Zhengzhou, Hui Zhengtang Pharmaceutical Technology Co., Ltd produces, treatment rheumatalgia 100 examples, wherein male's 50 examples, women's 50 examples.
2, medicament selection
Treatment group: emplastrum of the present invention (according to embodiment 1 method preparation), 8g/ pastes, and one pastes/2 days.
Matched group: treating rheumatism and strengthening bone pastes, and Hui Zhengtang Pharmaceutical Technology Co., Ltd produces by Zhengzhou, 8g/ pastes, and one pastes/2 days.
3, diagnostic criteria
1. medical history: the invasion and attack history that has wind-cold damp pathogen.
2. symptom: there are joint or muscular soreness, numb, pain, even severe pain, movable difficulty, meets cold aggravation.
3. sign: the joint of getting involved is because of function limitation due to pain, but alleviate after activity, majority of cases is pain pneumonedema only, and minority case is in periarticular mild swelling (without red heat).
4. x ray examination: except the visible soft tissue swelling of minority case, generally without sclerotin change.
5. lab testing: erythrocyte sedimentation rate is most normal, and minority is slightly fast, and it is normal that antistreptolysin 0, rheumatoid factor, routine blood test etc. all belong to.
6. prognosis: deformity is not stayed in the joint of getting involved after catabasis or healing, and joint function recovery is normal.
4, criterion of therapeutical effect
" in cure the desease Standardization of diagnosis and curative effect " of implementing with reference to State Administration of Traditional Chinese Medicine 1994 drafted as follows:
Clinical recovery: tcm clinical practice symptom, sign disappear or substantially disappear;
Effective: tcm clinical practice symptom, sign obviously change;
Effective: tcm clinical practice symptom, sign all take a favorable turn;
Invalid: tcm clinical practice symptom, sign are all not improved;
5, therapeutic outcome
Table 1 is treated the Comparison of therapeutic of rheumatalgia
| Group | Treatment number | Recovery from illness | Effective | Effectively | Invalid | Total effective rate |
| Treatment group | 100 | 65 | 20 | 13 | 2 | 98％ |
| Matched group | 100 | 58 | 13 | 9 | 20 | 80％ |
6, conclusion
Treatment group and matched group stick respectively three courses for the treatment of (12 days each courses for the treatment of), the treatment group invention emplastrum (according to embodiment 1 method preparation) that loses money in a business, and matched group pastes treating rheumatism and strengthening bone and pastes.Therapeutic outcome shows, treatment group total effective rate 98% of the present invention, matched group total effective rate 80%.Treatment group of the present invention is obviously better than matched group.
7, discuss
Radix Kansui in pharmaceutical composition crude drug of the present invention, bitter sweet cold, poisonous, enter spleen, lung, kidney channel, removing mass is poly-, removing water retention by purgation drink." book on Chinese herbal medicine is newly organized " calls it " broken addiction heavily fortified point gathers as god ".Venenum Bufonis, sweet, acrid, warm, poisonous, function removing toxic substances, detumescence, pain relieving, " book on Chinese herbal medicine converges and says ": " Venenum Bufonis, current twelve channels and collaterals, internal organs, pleurodiaphragmatic in terspace, joint Zhu Chu." " can dissolve the stagnant all diseases of the strongly fragrant heap soil or fertilizer over and around the roots of all stasis of bloods ".Rhizoma Paridis: toil, cold, poisonous.Enter the heart, Liver Channel.Heat-clearing and toxic substances removing, antiasthmatic-antitussive, arresting convulsion relieves dizziness, high fever, infantile convulsions, epilepsy, etc." the SHENGCAO property of medicine is standby to be wanted ": the circulation of qi promoting of enriching blood, strong lean kidney, hundred poison can disappear.Calculus Macacae Mulattae: the micro-salty double hardship of nature and flavor, cold flat, nontoxic.Return lung, stomach two warps.Removing phlegm to relieve convulsion, heat-clearing and toxic substances removing.Control expectorant dyspnea of heat type and cough, pediatric epilepsy scared, scrofula sucutaneous nodule.Gekko Swinhonis: salty, cold.Slightly poisonous.Dispel the wind, active, eliminating stagnation.Osteomyelitis, tuberculous lymphadenitis, tumor.Arresting convulsion, removing toxic substances.Control paralysis due to windstroke, severe and migratory arthralgia pain, wind-phlegm infantile convulsion, scrofula, malignant boil.Lignum Pini Nodi: meridian distribution of property and flavor is bitter, and temperature, returns Liver Channel.Effect is dispeiling pathogenic wind and removing dampness, pain relieving.For main anemofrigid-damp arthralgia, severe and migratory arthralgia pain; Foot numbness flaccidity is soft; Traumatic pain.Caulis Trachelospermi: cold nature, bitter in the mouth.Dispelling wind and removing obstruction in the collateral, removing heat from blood detumescence.For rheumatism pyretic arthralgia, the contracture of muscle arteries and veins, soreness of waist and knee joint, sore throat, carbuncle, injury from falling down." Jiangxi medical herbs ": dispelling, collateral-activating, cooling blood for hemostasis.Curing arthritis, pulmonary tuberculosis, spits blood, traumatic hemorrhage, acute toothache, scrofula, venom.Rhizoma Et Radix Notopterygii: nature and flavor: acrid in the mouth; Bitter; Warm in nature.Gui Jing: return bladder; Kidney channel.Effect: loose exterior cold; Wind-damp dispelling; Profit joint; Pain relieving." product remittance essence is wanted ": main all joints being painful all over, flesh table eight winds coming from eight orientations harmful climatic factors, except new and old rheumatism, arranges slough cellulitis skin ulcer.Folium Photiniae (Folium Photiniae serrulatae): meridian distribution of property and flavor: pungent, hardship, flat; Slightly poisonous.Function cures mainly: dispels the wind, and dredging collateral, kidney tonifying.For pathogenic wind-warm arthralgia pain, aching pain in waist and back, the foot and knee being feeble, migraine Shennong's Herbal: " support kidney qi, interior impairment of YIN declines, relieving rigidity of muscles and joints fur.”。Scolopendra: salty, pungent, temperature.Poisonous.Return liver, spleen, lung meridian.Relieve internal heat anticancer, relieving spasm by calming endogenous wind, move back inflammation and control skin ulcer.Sanguis Draxonis, Gan Xian, flat, enter the heart, Liver Channel, function eliminating stasis to stop pain, hemostasia and promoting granulation, cures mainly ecchymoma due to internal injury, and traumatic injury is lost, " detailed outline ": " interchannel Liu Shi cloud: Sanguis Draxonis dehematize pain, for the panacea of blood being.Olibanum, Myrrha, though main disorders of blood, and double enter edema caused by disorder of QI, this specially in blood system person also "." Bencao Jingshu ": " salty master disappears for Sanguis Draxonis, sweet main benefit, the key medicine of dissipating blood stasis blood, tissue regeneration promoting blood." Herba Erodii: nature and flavor hardship, for pungent, flat.Gui Jing returns liver, kidney, large intestine channel.Function cures mainly dispels rheumatism.For rheumatic arthralgia." Traditional Chinese Medicine in Sichuan will ": expelling wind and cold.Control cough due to lung-heat, the goiter that disappears, is coated with carbuncle pyogenic infections from tumour or sore, helps digestion long-pending glutted.The all medicine merging of crude drug of the present invention have promoting the flow of QI in the collateral by warming the meridian, and blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain, evil-wind expelling and dampness removing, have good therapeutical effect to treatment rheumatalgia, and have no side effect.
Experimental example two, model case
Case 1: Wu, female, 46 years old, teacher.Nineteen ninety is diagnosed as rheumatoid arthritis.The little arthralgia swelling of both hands joint stuffiness when medical.It is obvious that play ankylosis morning, movable rear improvement.Finger is fusiformis swelling, and metacarpophalangeal joints is ulnar deviation deformity, and dysfunction can not be adhered to teaching, and life can not be taken care of oneself completely.By the invention emplastrum that loses money in a business (according to embodiment 1 method preparation) treatment two courses for the treatment of (12 days course for the treatment of), arthralgia is clearly better, function of joint is obviously improved, and two lives course for the treatment of of continual cure can be taken care of oneself completely, substantially recover on inspection normal.
Case 2: Chen, female, 45 years old.Patient starts to occur bilateral bilateral articulations digitorum manus symmetry pain the year before, Relapse rate outbreak, time heavy when light, nearly two weeks carrys out aggravation,, the little joint of extremity symmetry red and swollen heat pain when medical, taking bilateral articulations digitorum manus and bilateral knee arthralgia as main, joint stuffiness, movable difficulty.Joint obtains cold easypro, and pain can not be touched, and plays ankylosis morning, after activity, take a turn for the better to some extent, and the heat that occurs together, aversion to wind, thirsty.Diagnostics classes rheumatic arthritis (wind heat arthralgia chiefly caused by damp pathogen type).The application of the invention ointment is (according to embodiment 2 method preparations, every day 2 times) treatment, after the course for the treatment of (12 days course for the treatment of), symptom obviously alleviates, and continues to use three courses for the treatment of, just can be freely movable, be completely recovered after using again the after treatment course for the treatment of.
Case 3: Wu, man, 65 years old.Symptom: nineteen ninety is diagnosed as rheumatoid arthritis.The little arthralgia swelling of both hands joint stuffiness when medical.It is obvious that play ankylosis morning, movable rear improvement.Finger is fusiformis swelling, and metacarpophalangeal joints is ulnar deviation deformity, and dysfunction can not be adhered to teaching, and life can not be taken care of oneself completely.The application of the invention spray is (according to embodiment 3 method preparations, every day 2 times) treatment two courses for the treatment of (12 days each courses for the treatment of), arthralgia is clearly better, function of joint is obviously improved, three lives course for the treatment of of continual cure can be taken care of oneself completely, substantially recover on inspection normal.
Case 4: Chen, female, 45 years old.Patient starts to occur bilateral bilateral articulations digitorum manus symmetry pain the year before, Relapse rate outbreak, time heavy when light, nearly two weeks carrys out aggravation, and the little joint of extremity symmetry red and swollen heat pain when medical, taking bilateral articulations digitorum manus and bilateral knee arthralgia as main, joint stuffiness, movable difficulty.Joint obtains cold easypro, and pain can not be touched, and plays ankylosis morning, after activity, take a turn for the better to some extent, and the heat that occurs together, aversion to wind, thirsty.Diagnostics classes rheumatic arthritis (wind heat arthralgia chiefly caused by damp pathogen type).Obviously alleviate by symptom after sticking a course for the treatment of (12 days courses for the treatment of) of patch of the present invention (according to embodiment 5 methods preparations), continue to stick two courses for the treatment of, just freely activity, is completely recovered after continuing again to stick a course for the treatment of.
Following embodiment all can realize the effect of above-mentioned experimental example.
Embodiment 1 emplastrum
Add conventional adjuvant to make emplastrum according to common process said medicine, 8g/ pastes, 2 days/paste.
Embodiment 2 ointments
Add conventional adjuvant to make ointment according to common process said medicine, every order 2 times.
Embodiment 3 sprays
Said medicine is added to the agent of conventional adjuvant granulation according to common process.
Embodiment 4 liniments
Add conventional adjuvant to make liniment according to common process said medicine.
Embodiment 5 emplastrumes
Venenum Bufonis 10kg Gekko Swinhonis 10kg Caulis Trachelospermi 10kg
Rhizoma Et Radix Notopterygii 10kg Scolopendra 10kg Sanguis Draxonis 10kg
Add conventional adjuvant to make emplastrum according to common process said medicine, 8g/ pastes, 2 days/paste.
Embodiment 6 tinctures
Venenum Bufonis 7kg Gekko Swinhonis 13kg Caulis Trachelospermi 7kg
Rhizoma Et Radix Notopterygii 13kg Scolopendra 7kg Sanguis Draxonis 13kg
Add conventional adjuvant to make tincture according to common process said medicine.
Embodiment 7 ointments
Venenum Bufonis 13kg Gekko Swinhonis 7kg Caulis Trachelospermi 13kg
Rhizoma Et Radix Notopterygii 7kg Scolopendra 13kg Sanguis Draxonis 7kg
Add conventional adjuvant to make ointment according to common process said medicine, 2 times on the one.
Claims (6)
1. a pharmaceutical composition for the treatment of rheumatalgia, is characterized in that, the crude drug of this pharmaceutical composition consists of:
2. pharmaceutical composition as claimed in claim 1, is characterized in that, the crude drug of this pharmaceutical composition consists of:
3. pharmaceutical composition as claimed in claim 1, is characterized in that, the crude drug of this pharmaceutical composition consists of:
4. pharmaceutical composition as claimed in claim 1, is characterized in that, the crude drug of this pharmaceutical composition consists of:
5. the pharmaceutical composition as described in one of claim 1-4, is characterized in that this pharmaceutical composition adds conventional adjuvant to make the emplastrum of clinical acceptance, spray, ointment, liniment or tincture according to common process.
6. the application of the pharmaceutical composition as described in one of claim 1-4 in the medicine of preparation treatment rheumatalgia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210286475.2A CN102805791B (en) | 2012-08-14 | 2012-08-14 | Drug composition for treating rheumatic pain |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210286475.2A CN102805791B (en) | 2012-08-14 | 2012-08-14 | Drug composition for treating rheumatic pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102805791A CN102805791A (en) | 2012-12-05 |
| CN102805791B true CN102805791B (en) | 2014-07-23 |
Family
ID=47229775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210286475.2A Expired - Fee Related CN102805791B (en) | 2012-08-14 | 2012-08-14 | Drug composition for treating rheumatic pain |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102805791B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101670078A (en) * | 2008-09-11 | 2010-03-17 | 彭丽英 | External medicament cervical ointment for treating cervical osteoarthritis |
| CN102441094A (en) * | 2011-12-15 | 2012-05-09 | 黄志明 | Medicinal composition for treating rheumatic arthritis and rheumatoid arthritis |
-
2012
- 2012-08-14 CN CN201210286475.2A patent/CN102805791B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101670078A (en) * | 2008-09-11 | 2010-03-17 | 彭丽英 | External medicament cervical ointment for treating cervical osteoarthritis |
| CN102441094A (en) * | 2011-12-15 | 2012-05-09 | 黄志明 | Medicinal composition for treating rheumatic arthritis and rheumatoid arthritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102805791A (en) | 2012-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104523865B (en) | Medicine for treating breast diseases | |
| CN108310320A (en) | A kind of externally applied drug and preparation method thereof for treating gout | |
| CN105497441A (en) | Plaster for treating arthralgia | |
| CN105106797A (en) | Traditional Chinese medicine nursing composition for treating tenosynovitis | |
| CN101983644A (en) | Medicament for treating sequelae of apoplexy | |
| CN104984148B (en) | A kind of clinical Chinese medicine wound care compositions | |
| CN102441094B (en) | Medicinal composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN103845429A (en) | Traditional Chinese medicine for treating chronic hepatitis | |
| CN103908600B (en) | The external used medicine for the treatment of rheumatoid arthritis damp-heat arthralgia resistance card and preparation method | |
| CN104069355A (en) | Medicinal composition for treating rheumatic arthritis and rheumatoid arthritis | |
| CN102805791B (en) | Drug composition for treating rheumatic pain | |
| CN102872252B (en) | Medicinal composition for treating rheumatic pain | |
| CN102861195B (en) | Drug composition for treating rheumatism pain | |
| CN101961455A (en) | Traditional Chinese medicine for treating chronic colitis disease | |
| CN105106337A (en) | Thunder god vine medical wine for treating rheumatoid arthritis | |
| CN104324285A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN104189273A (en) | Traditional Chinese medicine used for treating thrombophlebitis | |
| CN103550471A (en) | Traditional Chinese medicine (TCM) composition for treating Bi pain | |
| CN108524697A (en) | A kind of drug for treating prostatitis and hyperplasia | |
| CN102389506B (en) | Pharmaceutical composition for treating rheumatism and rheumatoid arthritis | |
| CN110420305B (en) | Traditional Chinese medicine composition for treating chronic muscle injuries and preparation method thereof | |
| CN102274336B (en) | Medicine composition for treating rheumatoid arthritis | |
| CN106822313A (en) | A kind of preparation method of blood-activating and stasis-removing decoction | |
| CN106361840A (en) | Traditional Chinese medicine composite used for treating rheumatism and preparing method thereof | |
| CN104645224A (en) | Traditional Chinese medicine preparation for treating costal chondritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140723 Termination date: 20150814 |
|
| EXPY | Termination of patent right or utility model |